Time to Invest in L...
Health Care: Drugs
Venaxis Inc (APPY: NASDAQ)
$1.30 -0.06 | -4.41%
05/24/13 - 04:00 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -9.21M | -10.21M | -13.34M | -15.52M |
| Operating Gains/Losses | 407.18K | -938.90K | 0.00 | 0.00 |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 35.02K | 38.16K | -25.22K | 15.24K |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 322.42K | 232.74K |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 32.21K | 284.54K | -419.38K | 662.31K |
| (Decrease) Increase In Other Current Liabilities | 273.65K | 30.77K | -222.65K | 167.92K |
| (Increase) Decrease In Other Working Capital | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Cash Items | 2.16M | 1.61M | 2.47M | 2.29M |
| Net Cash From Continuing Operations | -5.49M | -8.33M | -10.71M | -11.36M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -5.49M | -8.33M | -10.71M | -11.36M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 2.83M | 2.97M | 5.21M | 7.44M |
| Purchases of Property, Plant & Equipment | -156.34K | -90.10K | -501.41K | -595.95K |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | -2.99M | -1.04M | -7.63M | -2.31M |
| Other Cash from Investing Activities | 0.00 | -228.16K | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -316.12K | 1.61M | -2.92M | 4.53M |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 15.15M | 1.46M | 9.41M | 8.73M |
| Repayment of Long-Term Debt | -1.33M | -673.90K | -236.16K | -350.62K |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Cash From Financing Activities | 13.81M | 782.16K | 9.17M | 8.38M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | 8.01M | -5.94M | -4.46M | 1.55M |
Portfolios with APPY
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- UserSUPRATRADE-2709091838
- UserBrahmsian's Debt/Equity Por...
- UserBrahmsian's Financially Sou...
- Userdan vosika Portfolio 1
- Usergame on
- Userdreamerl3oi Portfolio 1
- Useremannn Portfolio 1
Latest APPY Headlines from TheStreet
- 5 Biotech Stocks Under $10 Moving Higher 01.30.13 | 08:01 am
- 5 Breakout Stocks: Must-See Charts 12.21.12 | 05:12 pm
- 5 Stocks Under $10 Set to Soar Higher 09.27.12 | 01:09 pm
- 4 Biotech Stocks Under $10 Making Big Moves 09.11.12 | 02:09 pm
- Biotech Sector Weekly Rewind 11.13.10 | 07:11 am
- Vantage Drilling, First M&F: Volume Movers 07.20.10 | 07:07 am
- AspenBio Finds Fault Afar for Failure 07.20.10 | 06:07 am
- Biotech Stock Mailbag: Spectrum Pharma 06.18.10 | 07:06 am
- Hellenic Telecom, AspenBio Pharma: Midday Volume Plays 06.07.10 | 12:06 pm
- Stock Offerings: Navios Maritime 04.30.10 | 11:04 am
Press Releases for APPY
- Venaxis Announces Pricing Of Offering Of Common Stock And Warrants - PR Newswire 05.23.13 | 07:05 pm
- Venaxis Appoints SomaLogic CMO And Former Pfizer Executive Stephen A. Williams, M.D., Ph.D., To Board Of Directors - PR Newswire 04.18.13 | 04:04 pm
- Venaxis Advances Pivotal U.S. Study And Accelerates European Market Development For APPY1 Blood-based Appendicitis Test - PR Newswire 03.26.13 | 04:03 pm
- Venaxis To Provide Fourth Quarter 2012 Business Update - PR Newswire 03.19.13 | 07:03 am
- Venaxis Secures Additional European Commercial Development Agreements For APPY1 - PR Newswire 03.18.13 | 07:03 am
- Venaxis To Present At 25th Annual ROTH Conference - PR Newswire 03.11.13 | 04:03 pm
- Venaxis Executes First Commercial Development Agreement And Receives Purchase Order From EMELCA Bioscience For Initial EU Launch - PR Newswire 02.07.13 | 07:02 am
- Venaxis Initiates Patient Enrollment For APPY1 Pivotal Study - PR Newswire 01.15.13 | 07:01 am
- Venaxis Obtains CE Mark For APPY1 Appendicitis Test - PR Newswire 01.07.13 | 04:01 pm
- Venaxis Files For CE Mark And Prepares For European Commercialization - PR Newswire 12.21.12 | 07:12 am
Partner Headlines for APPY
- Weekly CFO Buys Highlight: CPRX, APPY, MEI, MNKD - GuruFocus 07.09.12 | 01:07 pm
- Weekly Market Wrap: Markets SHAKE, Microsoft's NEW Product, Bank Ratings SLASHED - Wall St. Cheat Sheet 06.23.12 | 09:06 am
- P&G SHAVES Profit Outlook and 4 Hot Stocks to Watch - Wall St. Cheat Sheet 06.20.12 | 12:06 pm
- Market Wrap: Oil SPILLS Lower, Microsoft RALLIES, Operation TWIST - Wall St. Cheat Sheet 06.20.12 | 10:06 am
- Morning Market Losers - Benzinga 06.20.12 | 09:06 am
- Ultimate Market Recap: Iffy Adobe Guidance, Jabil Jumps 7% - Wall St. Cheat Sheet 06.20.12 | 08:06 am
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 06.19.12 | 09:06 am
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 06.05.12 | 09:06 am
- Morning Market Losers - Benzinga 12.19.11 | 09:12 am
- AspenBio Pharma Reports AppyScore(TM) ELISA-Based Pivotal Trial Results and Outlines Plans for AppyScore Cassette-Based Test - Benzinga 07.19.10 | 04:07 pm
